Tech was leading the way lower for stocks Wednesday. BTIG Chief Market Technician Jonathan Krinsky noted that while tech ...

Fintel reports that on November 27, 2024, BTIG upgraded their outlook for Embecta (NasdaqGS:EMBC) from Neutral to Buy. Analyst Price Forecast Suggests 20.45% Downside As of November 21, 2024, the ...

Specialty Finance Analyst Caintic holds a meeting with CEO Howard and CFO McCamey in Boston on December 4 hosted by BTIG.Don't Miss our Black ...

BTIG analyst Michael Gorman raised the firm’s price target on Agree Realty (ADC) to $78 from $74 and keeps a Buy rating on the shares. Agree ...

Embecta (EMBC) stock gains as BTIG upgrades the stock citing an end to its patch pump program announced with its Q4 FY24 results. Read more here.

Alector (NASDAQ:ALEC – Free Report) had its target price lowered by BTIG Research from $16.00 to $5.00 in a research note ...

JPMorgan Chase & Co.’s equity strategy team, led for years by Marko Kolanovic until his departure earlier in 2024, has turned ...

It isn't all bad news, said John Krinsky, chief market technician at BTIG, in a Wednesday client note. Tech's XLK 1.5% fall ...

Notable insider trades include Wang Junyuan Jerry, CEO, ANHEART THERAPEUTICS LTD. at Nuvation Bio Inc (NUVB), who sold 56361 shares on Nov 11 ’24, at $2.89 each, totaling $0.16 million.

On Tuesday, Replimune Group Inc (REPL) stock saw a modest uptick, ending the day at $14.38 which represents a slight increase of $1.12 or 8.45% from the prior close of $13.26. The stock opened at $13.

Embecta (EMBC) closed up more than +9% after BTIG LLC upgraded the stock to buy from neutral with a price target of $26. Ambarella (AMBA) closed up more than +5% after reporting Q3 adjusted EPS of 11 ...

A selloff in the world’s largest technology companies dragged down stocks, while the latest economic data gave support to the Federal Reserve’s cautious stance on rate cuts.